Your browser doesn't support javascript.
loading
A potential SARS-CoV-2 variant of interest (VOI) harboring mutation E484K in the Spike protein was identified within lineage B.1.1.33 circulating in Brazil
Paola C Resende; Tiago Graf; Anna C D Paixao; Luciana Appolinario; Renata S Lopes; Ana C F Mendonca; Alice S B da Rocha; Fernando C Motta; Lidio G L Neto; Ricardo Khouri; Camila I de Oliveira; Pedro Santos-Muccillo; Joao F Bezerra; Dalane L F Teixeira; Irina Riediger; Maria C Debur; Rodrigo Ribeiro-Rodrigues; Anderson B Leite; Cliomar A do Santos; Tatiana S Gregianini; Sandra B Fernandes; Andre F L Bernardes; Andrea C Cavalcanti; Fabio Miyajima; Claudio Sachhi; Tirza Mattos; Cristiano F da Costa; Edson Delatorre; Gabriel L Wallau; Felipe G Naveca; Gonzalo Bello; Marilda M Siqueira.
Affiliation
  • Paola C Resende; Laboratory of Respiratory Viruses and Measles, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
  • Tiago Graf; Instituto Goncalo Moniz, Fundacao Oswaldo Cruz, Salvador, Brazil.
  • Anna C D Paixao; Laboratory of Respiratory Viruses and Measles, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
  • Luciana Appolinario; Laboratory of Respiratory Viruses and Measles, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
  • Renata S Lopes; Laboratory of Respiratory Viruses and Measles, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
  • Ana C F Mendonca; Laboratory of Respiratory Viruses and Measles, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
  • Alice S B da Rocha; Laboratory of Respiratory Viruses and Measles, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
  • Fernando C Motta; Laboratory of Respiratory Viruses and Measles, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
  • Lidio G L Neto; Laboratorio Central de Saude Publica do Maranhao (LACEN-MA)
  • Ricardo Khouri; Instituto Goncalo Moniz, Fundacao Oswaldo Cruz, Salvador, Brazil.
  • Camila I de Oliveira; Instituto Goncalo Moniz, Fundacao Oswaldo Cruz, Salvador, Brazil.
  • Pedro Santos-Muccillo; Instituto Goncalo Moniz, Fundacao Oswaldo Cruz, Salvador, Brazil.
  • Joao F Bezerra; Universidade Federal da Paraiba (UFPB)
  • Dalane L F Teixeira; Laboratorio Central de Saude Publica da Paraiba (LACEN-PB)
  • Irina Riediger; Laboratorio Central de Saude Publica de Parana (LACEN-PR). Curitiba, Parana, Brazil.
  • Maria C Debur; Laboratorio Central de Saude Publica de Parana (LACEN-PR). Curitiba, Parana, Brazil.
  • Rodrigo Ribeiro-Rodrigues; Laboratorio Central de Saude Publica do Espirito Santo (LACEN-ES)
  • Anderson B Leite; Laboratorio Central de Saude Publica do Alagoas (LACEN-AL)
  • Cliomar A do Santos; Laboratorio Central de Saude Publica de Sergipe (LACEN-SE). Aracaju, Sergipe, Brazil.
  • Tatiana S Gregianini; Laboratorio Central de Saude Publica do Rio Grande do Sul (LACEN-RS)
  • Sandra B Fernandes; Laboratorio Central de Saude Publica do Estado de Santa Catarina (LACEN-SC), Florianopolis, Santa Catarina, Brazil.
  • Andre F L Bernardes; Laboratorio Central de Saude Publica de Minas Gerais (LACEN-MG)
  • Andrea C Cavalcanti; Laboratorio Central de Saude Publica do Rio de Janeiro (LACEN-RJ)
  • Fabio Miyajima; Fundacao Oswaldo Cruz - Fiocruz Ceara
  • Claudio Sachhi; Instituto Adolfo Lutz (IAL)
  • Tirza Mattos; Laboratorio Central de Saude Publica do Amazonas, Manaus, Amazonas, Brazil
  • Cristiano F da Costa; Fundacao de Vigilancia em Saude do Amazonas, Manaus, Amazonas, Brazil
  • Edson Delatorre; Departamento de Biologia. Centro de Ciencias Exatas, Naturais e da Saude, Universidade Federal do Espirito Santo, Alegre, Brazil.
  • Gabriel L Wallau; Instituto Aggeu Magalhaes, Fundacao Oswaldo Cruz, Recife, Pernambuco, Brazil
  • Felipe G Naveca; Laboratorio de Ecologia de Doencas Transmissiveis na Amazonia (EDTA), Leonidas e Maria Deane Institute, Fiocruz
  • Gonzalo Bello; Laboratorio de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil.
  • Marilda M Siqueira; Laboratory of Respiratory Viruses and Measles, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Preprint in En | PREPRINT-BIORXIV | ID: ppbiorxiv-434969
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
The SARS-CoV-2 epidemic in Brazil was dominated by two lineages designated as B.1.1.28 and B.1.1.33. Two SARS-CoV-2 variants harboring mutations at the receptor-binding domain of the Spike (S) protein, designated as lineages P.1 and P.2, evolved within lineage B.1.1.28 and are rapidly spreading in Brazil. Lineage P.1 is considered a Variant of Concern (VOC) because of the presence of multiple mutations in the S protein (including K417T, E484K, N501Y), while lineage P.2 only harbors mutation SE484K and is considered a Variant of Interest (VOI). Here we report the identification of a new SARS-CoV-2 VOI within lineage B.1.1.33 that also harbors mutation SE484K and was detected in Brazil between November 2020 and February 2021. This VOI displayed four non-synonymous lineage-defining mutations (NSP3A1711V, NSP6F36L, SE484K, and NS7bE33A) and was designated as lineage N.9. The VOI N.9 probably emerged in August 2020 and has spread across different Brazilian states from the Southeast, South, North and Northeast regions.
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Language: En Year: 2021 Document type: Preprint
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Language: En Year: 2021 Document type: Preprint